Tag - Echelon Wealth Partners

Markets

Echelon ascribes Top Pick status to Centric Health, Protech Home Medical

Echelon Wealth Partners ascribed Top Pick status to Centric Health (TSX:CHH) and Protech Home Medical (TSXV:PTQ), while maintaining “buy” ratings and price targets of 25 cents and $2.50, respectively. Shares of Centric...

April 3, 2020

Markets

Echelon rates Correvio Pharma “tender” after takeover bid from ADVANZ Pharma

Echelon Wealth Partners moved its rating for Correvio Pharma (NASDAQ, TSX:CORV) to “tender” from “hold” after ADVANZ Pharma (TSX:ADVZ) agreed to acquire Correvio, which closed at 35 cents on March 17. Analyst Doug Loe...

March 17, 2020

Markets

Echelon starts Protech Home Medical at buy; PT $2.50

Echelon Wealth Partners launched overage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $2.50. The stock closed at 91 cents on Jan. 22. “We believe the firm is well positioned within [the...

January 22, 2020

Markets

Echelon reiterates Acasti Pharma, Antibe Therapeutics as top picks

Echelon Wealth Partners reiterated top pick status to Acasti Pharma (TSXV:ACST) and Antibe Therapeutics (TSXV:ATE). Acasti is developing an omega-3-based therapeutic for the treatment of hyperglyceridemia. Analyst Doug...

January 9, 2020

Developments

Echelon adds top pick status to Immunovaccine

Echelon Wealth Partners ascribed 2017 top pick status to Immunovaccine (TSX:IMV; OTCQX:IMMVF) while maintaining a “speculative buy” rating and $2.75 price target. The stock closed at $1.24 on Oct. 11. Analyst Doug Loe...

October 12, 2017

Tag - Echelon Wealth Partners

Echelon ascribes Top Pick status to Centric Health, Protech Home Medical

Echelon rates Correvio Pharma “tender” after takeover bid from ADVANZ Pharma

Echelon starts Protech Home Medical at buy; PT $2.50

Echelon reiterates Acasti Pharma, Antibe Therapeutics as top picks

Echelon adds top pick status to Immunovaccine

General

More